The Legal 500 > DLA Piper > Sydney, AUSTRALIA

DLA Piper

LEVEL 22, NO.1 MARTIN PLACE, SYDNEY, NSW 2000, AUSTRALIA

Tel:: Work +61 2 9286 8000
Fax:: Fax +61 2 9286 8007
DX:: 107 SYDNEY

Email:

Web:: www.dlapiper.com

Aarhus, Abu Dhabi, Accra, Addis Ababa, Al-Khobar, Algiers and 121 more

The firm: DLA Piper is a global law firm with lawyers in the Americas, Asia Pacific, Europe, Africa and the Middle East, positioning it to help companies with their legal needs around the world.

DLA Piper strives to be the leading global business law firm by providing quality and value to clients every day. The firm achieves this through practical and innovative legal solutions that help clients succeed, and by delivering consistently across its full-service platform.

Areas of practice: Clients range from multinational, Global 1000 and Fortune 500 enterprises to emerging companies developing industry-leading technologies, as well as all levels of government and public sector bodies. The firm is a trusted advisor to clients across Asia Pacific, those looking to expand their operations overseas, and international clients looking to enter the Asia Pacific market.

DLA Piper advises clients across a full range of services and sectors, with particular expertise in the following industries: banking and financial services; energy; government; healthcare; hospitality and leisure; insurance; life sciences; media, sports and entertainment; mining; real estate; technology; telecommunications; and transport.

DLA Piper was created in 2005 by the merger of Dibb Lupton Alsop, Piper Rudnick and Gray Cary, followed by aggressive growth in the CIS, Germany, Spain, Asia Pacific, the Middle East and further recent growth across the Americas, including Canada and Mexico, in Africa, the Nordic region, as well as further integration with DLA Piper New Zealand. The strategy was simple - to create a truly global firm capable of taking care of the most important legal needs of clients wherever they do business.

Contacts
 
Amber Matthews

Number of lawyers: 4,200
at this office: 100+

Languages
English
French
German
Spanish
Greek
Afrikaans
Arabic
Assyrian
Bengali
Cantonese
Danish
Dutch
Hebrew
Hindi
Hungarian
Indonesian
Italian
Japanese
Korean
Macedonian
Malay
Mandarin
Polish
Portuguese
Punjabi
Russian
Swahili
Swedish
Tagalog
Tamil
Turkish
Ukrainian
Vietnamese

Above material supplied by DLA Piper.

Search News and Articles

Legal Developments by:
DLA Piper LLP (US)

Sentencing guidelines for corporate manslaughter

In February 2010 the Sentencing Guidelines Council (the SGC) issued definitive guidelines to courts on imposing appropriate sentences for corporate manslaughter and health and safety offences causing death. The SGC states that fines imposed on companies found guilty of corporate manslaughter should not fall below £500,000, while fines in respect of health and safety offences that are a significant cause of death should be at least £100,000. Crucially, the SGC declined to provide for a fixed link between the imposed fine and the turnover or profitability of the offending company. 

- DLA Piper UK LLP

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to

Foyen has advised Mandalay Resources in 32 Million USD share issue

Foyen has advised Canadian mining company Mandalay Resources Corporation inits marketed public offering of shares (subscription rights) on the Toronto stock exchange for aggregate gross proceeds of 43 million CAD (32 MUSD).Mandalay is the 100 % owner of the Bjorkdal gold mine in northern Sweden and the transaction has required legal opinions regarding all companies and permits in the Swedish business operation.

- Foyen Advokatfirma AB
Foyen recruits lawyer from the Court of Appeal

Foyen Advokatfirma has recruited lawyer Erika Stjärnström from the Göta Court of Appeal. Erika has joined the law firm's Construction business sector, writes Foyen in a press release .

- Foyen Advokatfirma AB
UNEXPLAINED WEALTH ORDERS: THEIR POTENTIAL AND THE RIGHT WAY TO RESPOND IF FACED WITH ONE

Aziz Rahman considers why we may see an increase inunexplained wealth orders (UWO’s) and the implications for law enforcement and individuals.

- Rahman Ravelli Solicitors
AVELLUM advises on IBRD-supported financing for Ukraine

AVELLUM acted as the Ukrainian legal counsel to the Ministry of Finance of Ukraine in connection with two syndicated EUR-denominated facilities arranged by Deutsche Bank in December 2018 and March 2019 for the total amount equivalent to approximately USD1 billion.

- Avellum
AVELLUM advises EBRD and BSTDB on financing of one of largest solar projects in Ukraine

AVELLUM acted as the Ukrainian legal counsel to the European Bank for Reconstruction and Development (“EBRD ”) and the Black Sea Trade and Development Bank (" BSTDB ") in connection with senior secured loans in the total amount of up to EUR36.3 million to Rengy Bioenergo LLC (“Loans ”).

- Avellum

Gulbenkian Andonain discuss NEW Tier 1 Start-Up Visa and the NEW Tier 1 Innovator Visa

The document entitled "Statement of Changes to Immigration Rules" which was released by the House of Commons on the 7th March 2019, outlined and advised us on a number of changes that will come into place that will affect the Tier 1 Investor Visa amongst other visa programmes and schemes. The latest article on our website discusses both of these new UK business visa routes. Our immigration lawyers London are already up to date on all of the required information for both the NEW Tier 1 Start-Up Visa and the NEW Tier 1 Innovator Visa .

- Gulbenkian Andonian

Upcoming Changes to the UK Tier 1 Investor Visa

According to the new document from the House of Commons on March 7th 2019 titled “Statement of Changes to Immigration Rules”, a number of changes will come into place that affecting the Tier 1 UK Investor Visa programme amongst other visa programmes and schemes. Read about them in our latest article .

- Gulbenkian Andonian

Illegal advertisement of effect of a medicinal product

It is illegal to advertise a specific effect attributed to a medicinal product if said effect is based merely on laboratory tests and has not been demonstrated in relation to humans.

- GRP Rainer LLP

Brexit and non-EU Immigration

There is no doubt that the UK has to date benefited immensely from visa-free EU immigration to the extent that visa conditions and caps on non-EU migrant have undermined and overshadowed the ability of this group to play a prominent role in British industry and commerce and in its expanding and overburdened NHS service. It is the view of Gulbenkian Andonian however, that after Brexit, there should be a noticeable change in those skilled non-EU migrants contributing to British society in a meaningful way.

- Gulbenkian Andonian

Gulbenkian Andonian Solicitors discuss Post Brexit scenarios - EU Nationals and Salient Immigration

From 1 January 2021 everyone except for British and Irish citizens will be subject to immigration control in the UK. Gulbenkian Andonian solicitors has already published an article on this topic of post- Brexit immigration and has discussed the case of EU nationals and family members after Brexit, you can find that article here as one of many in our blog .

- Gulbenkian Andonian